Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-277 · 1 trial · 1 indication
Cmax of ABBV-277
Tmax of ABBV-277
Terminal phase elimination rate constant (beta) of ABBV-277
Terminal phase elimination half-life of ABBV-277
AUCt of ABBV-277
AUCinf of ABBV-277
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study
| Arm | Type | Description |
|---|---|---|
| Group 1: ABBV-277-Dose A | EXPERIMENTAL | Participants will receive ABBV-277 Dose A on day 1 and followed for 196 days |
| Group 1: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and followed for 196 days |
| Group 2: ABBV-277-Dose B | EXPERIMENTAL | Participants will receive ABBV-277 Dose B on day 1 and followed for 196 days |
| Group 2: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and followed for 196 days |
| Group 3: ABBV-277-Dose C | EXPERIMENTAL | Participants will receive ABBV-277 Dose C on day 1 and followed for 196 days |
| Group 3: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and followed for 196 days |
| Group 4: ABBV-277-Dose D | EXPERIMENTAL | Participants will receive ABBV-277 Dose D on day 1 and followed for 196 days |
| Group 4: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and followed for 196 days |
| Group 5: ABBV-277-Dose E | EXPERIMENTAL | Participants will receive ABBV-277 Dose E on day 1 and day 2 and followed for 196 days |
| Group 5: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and day 2 and followed for 196 days |
| Name | Type | Description |
|---|---|---|
| ABBV-277 | DRUG | • Intravenous (IV) infusion |
| Placebo | DRUG | • Intravenous (IV) infusion |
Inclusion Criteria: * Body weight ≥ 35 kg * Body Mass Index (BMI) is ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile neurological examination, and ...
ABBV-277 is an investigational small molecule drug being developed by AbbVie Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been disclosed.
ABBV-277 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. The company sponsored the Phase 1 study of the compound in healthy adult participants.
ABBV-277 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The study enrolled 32 participants and was conducted in the United States.
ABBV-277 has been evaluated in one clinical trial, NCT07136103, titled A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants. The Phase 1 trial is completed, enrolled 32 healthy volunteers, and was conducted in the United States.
ABBV-277 is not approved. It is an investigational small molecule still in clinical development, with only a completed Phase 1 trial in healthy adult volunteers. No regulatory approval has been granted for this compound.
The Phase 1 trial of ABBV-277, NCT07136103, was a randomized, double-blind, controlled study in healthy adult participants aged 18 and older. It enrolled 32 participants of all sexes in the United States and assessed safety, tolerability, pharmacokinetics, and immunogenicity.